Phase ll trial of Amrubicin in Patients with Priviously Treated Advanced Non-Small Cell Lung Cancer - Phase ll trial of Amrubicin in Patients with Priviously Treated Advanced Non-Small Cell Lung Cancer

First Department of Surgery, Hamamatsu University School of Medicine0 个研究点目标入组 35 人开始时间: 2011年1月6日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients who have previously treated with chemotherapy containing amrubicin. 2) Patients with symptomatic brain metastasis. 3) Patients with massive uncontrolled pleural or pericardial effusion ,or ascites. 4) Patients with active severe infections 5) Patients with double cancer within 5 years. 6) Patients with active interstitial pneumonia recognized by chest X-ray. 7) Patients with serious drug allergic reactions. 8) Patients with active concomitant pregnancy. 9) Patients with cardiac infarction or unstable angina within 12 months. Patients need to recieve medications for their bad heart function. 10) Patients who have previously treated with a cumulative daunorubicin dose > 25 mg/kg, doxorubicin >500 mg/m2, epirubicin >900mg/m2, pirarubicin > 950mg/m2. 11) a serious or uncontrolled concomitant systematic disorder (active gastric or duodenal ulcer, uncontrolled diabetes mellitus, or cerebral infarction within 6 months.) 12) Inappropriate patients for this study judged by the physicians

发起方

First Department of Surgery, Hamamatsu University School of Medicine